Document is current
Any future updates will be listed below
-
Authors
Stok, Jorn E https://orcid.org/0000-0003-0990-0761
Oosenbrug, Timo https://orcid.org/0000-0002-7533-0595
ter Haar, Laurens R https://orcid.org/0000-0002-9237-0142
Gravekamp, Dennis https://orcid.org/0000-0002-6594-5983
Bromley, Christian P https://orcid.org/0000-0001-6203-6891
Zelenay, Santiago https://orcid.org/0000-0002-6865-3978
Reis e Sousa, Caetano https://orcid.org/0000-0001-7392-2119
van der Veen, Annemarthe G https://orcid.org/0000-0001-9324-3404
-
Funding
Funding for this research was provided by:
Cancer Research UK (FC00113)
Medical Research Council (FC001136)
Manchester Biomedical Research Centre
Cancer Research UK Manchester Centre (A19258)
Louis-Jeantet Foundation
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (09150171910070)
H2020 European Research Council (786674)
H2020 European Research Council (268670)
- License Information
-
More Information
Article History
Received: 20 September 2021
Revised: 7 January 2022
Accepted: 11 January 2022
First Online: 14 February 2022
Disclosure and competing interests statement
: CRS has an additional appointment as Professor in the Faculty of Medicine at Imperial College London. CRS is a founder of Adendra Therapeutics and owns stock options and/or is a paid consultant for Adendra Therapeutics, Bicara Therapeutics, Montis Biosciences, Oncurious NV, Bicycle Therapeutics and Sosei Heptares, all unrelated to this work. The other authors declare that they have no conflict of interest.
